A. H. Mostafid

发表

Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.

M. Babjuk, F. Montorsi, J. Witjes, 2010, European urology.

A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia.

M. S. Fletcher, A. H. Mostafid, N. Harrison, 1997, British journal of urology.

Electromotive Drug Administration of Local Anesthesia for Biopsy and Cystodiathermy of Recurrent Low Grade Bladder Tumors

S. Biers, A. H. Mostafid, 2009, Current Urology.

Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016".

M. Babjuk, R. Sylvester, E. Compérat, 2018, European urology focus.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).

A. Masson-Lecomte, M. Babjuk, R. Sylvester, 2021, European urology.

Non-muscle-invasive Bladder Cancer ( TaT 1 and CIS ) EAU Guidelines on

R. Sylvester, M. Rouprêt, P. Gontero*, 2016 .

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

The 2‐year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate

A. H. Mostafid, N. Harrison, P. Thomas, 2001, BJU international.

Interstitial radiofrequency therapy of the prostate: results of a pilot study.

M. S. Fletcher, A. H. Mostafid, N. Harrison, 1996, The Journal of urology.

Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.

T. H. van der Kwast, M. Babjuk, R. Sylvester, 2021, European urology oncology.

Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.

J. Witjes, R. Sylvester, J. Palou Redorta, 2015, European urology.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Shahrokh F. Shariat, Maximilian Burger, Richard Sylvester, 2019, European urology.

Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer

A. H. Mostafid, Rajinder Singh, A. Stewart, 2006, BJU international.

European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.

L. Kiemeney, T. H. van der Kwast, M. Babjuk, 2021, European urology.

Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.

M. Babjuk, Yuhong Yuan, R. Sylvester, 2017, European urology.

Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.

M. Babjuk, Yuhong Yuan, R. Sylvester, 2020, European urology focus.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.

M. Babjuk, R. Sylvester, S. Shariat, 2015, European urology.

Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.

L. Kiemeney, A. Masson-Lecomte, M. Babjuk, 2022, European urology oncology.

Time to re‐evaluate and refine re‐transurethral resection in bladder cancer?

A. H. Mostafid, 2016, BJU international.

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

A. Feber, P. Cooke, J. McGrath, 2020, BJU international.

Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?

L. Kiemeney, T. H. van der Kwast, M. Babjuk, 2019, Urologic oncology.

Is transurethral resection of the prostate safe and effective in the over 80-year-old?

M. S. Fletcher, A. H. Mostafid, D. Kontothanassis, 2001, Annals of the Royal College of Surgeons of England.

Predicting Outcomes in Bladder Cancer: Are We Any Good and Could We Do Better?

A. H. Mostafid, J. Cresswell, 2015, European urology.

Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups

A. Masson-Lecomte, M. Babjuk, R. Sylvester, 2022, European Urology.

T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum.

A. Masson-Lecomte, M. Babjuk, O. Cussenot, 2022, European urology focus.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.

M. Babjuk, R. Sylvester, S. Shariat, 2015, European urology.

Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer

S. Biers, A. H. Mostafid, A. Marco, 2007, International Urology and Nephrology.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.

M. Babjuk, R. Sylvester, S. Shariat, 2015, European urology.